Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Century Therapeutics, Inc. (IPSC : NSDQ)

• Company Description    Century Therapeutics Inc. is a cell therapy company. It involved in developing induced pluripotent stem cell -derived cell therapies in immuno-oncology. Century Therapeutics Inc. is based in PHILADELPHIA. Number of Employees: 78

• Price / Volume Information    Yesterday's Closing Price: $1.61 Daily Weekly Monthly 20 Day Moving Average: 893,829 shares Shares Outstanding: 181.07 (millions) Market Capitalization: $291.53 (millions) Beta: 1.67 52 Week High: $3.04 52 Week Low: $0.44 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -8.52% -9.13% 12 Week -20.30% -24.83% Year To Date 61.84% 42.82%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 25 N 38 th Street 12th Floor - PHILADELPHIA,PA 19104 USA ph: 267-817-5790 fax: - investor.relations@centurytx.com http://www.centurytx.com

• General Corporate Information    Officers Brent Pfeiffenberger - Chief Executive Officer and Chairman Douglas Carr - Senior Vice President; Finance & Operations Kimberly Blackwell - Director Han Lee - Director Martin Murphy - Director Peer Information Century Therapeutics, Inc. (GSAC) Century Therapeutics, Inc. (CASIF) Century Therapeutics, Inc. (ALCD.) Century Therapeutics, Inc. (OMNN) Century Therapeutics, Inc. (CGPI.) Century Therapeutics, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 15673T100 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/12/26 Share - Related Items Shares Outstanding: 181.07 Most Recent Split Date: (:1) Beta: 1.67 Market Capitalization: $291.53 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.12 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.51 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.25 Price/Cash Flow: 121.05 Price / Sales: - EPS Growth vs. Year Ago Period: 55.26% vs. Previous Quarter: -54.55% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/26 - - 06/30/26 - -49.51 03/31/26 - -49.89 ROA 09/30/26 - - 06/30/26 - -38.09 03/31/26 - -37.42 Current Ratio 09/30/26 - - 06/30/26 - 8.28 03/31/26 - 10.25 Quick Ratio 09/30/26 - - 06/30/26 - 8.28 03/31/26 - 10.25 Operating Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Net Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Pre-Tax Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Book Value 09/30/26 - - 06/30/26 - 1.29 03/31/26 - 1.47 Inventory Turnover 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Equity 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00 Debt-to-Capital 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00

Powered by Zacks Investment Research ©